Upcoming Login Downtime
We're updating the Biocentury.com platform login experience to make access more secure and reliable. As part of this update, logins will be temporarily unavailable on Sunday, March 16, from 4:00AM to 4:00PM GMT. We recognize the inconvenience and appreciate your understanding. Please check back after the maintenance period.
For updates, questions, or issues, please call us at +1 650-552-4224 or email us at support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Viridian Therapeutics Inc.
Headquarters: Boulder, CO, United States of America
Website: https://www.viridiantherape...
Year Founded: 2007
Status: Public
Industry Sector: HealthTechnology
CEO: Stephen Frank Mahoney, MBA
Number Of Employees: 143
Enterprise Value: $795,767,380
PE Ratio: -3.99
Exchange/Ticker 1: NASDAQ:VRDN
Exchange/Ticker 2: N/A
Latest Market Cap: $1,288,277,888
BioCentury | Dec 18, 2024
Product Development
Merck, iTeos dropping assets, Viridian data — BioCentury’s Clinical Report
Plus: Readouts from Sanofi-Teva, Bicycle and more
BioCentury | Dec 17, 2024
Product Development
Viridian taking on Amgen in TED market
Positive data from second Phase III trial of veligrotug in thyroid eye disease; this time in chronic setting
BioCentury | Sep 13, 2024
Finance
Public Equity Report: Biotech quintet raises $1.3B+ via follow-ons
Ionis tops list of five biotechs raising at least $200M in public offerings, along with Centessa, Viridian, Relay and Xencor; plus PIPEs keep flowing
BioCentury | Sep 12, 2024
Product Development
Clinical Report: AstraZeneca, Daiichi turn to precision medicine after OS miss for Dato-DXd
Plus: Results from Relay, Centessa, Viridian, Amgen and more
BioCentury | Apr 18, 2024
Management Tracks
Protego names Warner CEO
Plus: Foghorn hires Humer and updates from Javelin, Stoke, Sensorium, Theradaptive and more
BioCentury | Mar 29, 2024
Politics, Policy & Law
Small biotechs reveal reliance on Chinese CDMOs
SEC filings disclose potential negative impacts of Biosecure Act
BioCentury | Feb 17, 2024
Management Tracks
Agresta joining OnKure as CMO
Plus: Viridian hires Tousignant and an update from Ligand
BioCentury | Jan 19, 2024
Finance
Public equity roundup: Edgewise shares get lift after $240M offering
Plus offerings by Immatics, Viridion, Alector, LegoChem and more
BioCentury | Dec 20, 2023
Management Tracks
Abernethy leaving Verily for non-profit
Plus: CEO Wang leaving LianBio and more from Bicara and Hervolution, ImPact
BioCentury | Aug 31, 2023
Finance
Formulas for success from biotechs that leaped in value despite the downturn
Back to School 2023 identifies four themes among 17 companies that jumped a tier or increased their market cap over 200%
Items per page:
1 - 10 of 29